These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 14701983)
1. The clinical impact of camera-based positron emission tomography imaging in patients with recurrent colorectal cancer. Miller E; Lerman H; Gutman M; Figer A; Livshitz G; Even-Sapir E Invest Radiol; 2004 Jan; 39(1):8-12. PubMed ID: 14701983 [TBL] [Abstract][Full Text] [Related]
2. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912 [TBL] [Abstract][Full Text] [Related]
3. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma. Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521 [TBL] [Abstract][Full Text] [Related]
4. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969 [TBL] [Abstract][Full Text] [Related]
5. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. Kalff V; Hicks RJ; Ware RE; Hogg A; Binns D; McKenzie AF J Nucl Med; 2002 Apr; 43(4):492-9. PubMed ID: 11937593 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer]. Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351 [TBL] [Abstract][Full Text] [Related]
7. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241 [TBL] [Abstract][Full Text] [Related]
8. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Pecking AP; Mechelany-Corone C; Bertrand-Kermorgant F; Alberini JL; Floiras JL; Goupil A; Pichon MF Clin Breast Cancer; 2001 Oct; 2(3):229-34. PubMed ID: 11899417 [TBL] [Abstract][Full Text] [Related]
9. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Pelosi E; Deandreis D Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522 [TBL] [Abstract][Full Text] [Related]
10. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613 [TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography in colorectal cancer. Flamen P Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236 [TBL] [Abstract][Full Text] [Related]
12. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132 [TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949 [TBL] [Abstract][Full Text] [Related]
14. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Simó M; Lomeña F; Setoain J; Pérez G; Castellucci P; Costansa JM; Setoain-Quinquer J; Doménech-Torné F; Carrió I Nucl Med Commun; 2002 Oct; 23(10):975-82. PubMed ID: 12352596 [TBL] [Abstract][Full Text] [Related]
15. Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET. Montravers F; Grahek D; Kerrou K; Younsi N; Petegnief Y; de Beco V; Colombet-Lamau C; Talbot JN Nucl Med Commun; 2004 Feb; 25(2):105-13. PubMed ID: 15154697 [TBL] [Abstract][Full Text] [Related]
16. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351 [TBL] [Abstract][Full Text] [Related]
17. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281 [TBL] [Abstract][Full Text] [Related]
18. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474 [TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Watson AJ; Lolohea S; Robertson GM; Frizelle FA Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]